124I PET/CT与传统放射性碘显像在分化型甲状腺癌中的比较:综述
本综述纳入4项回顾性和10项前瞻性研究,共495例分化型甲状腺癌患者接受124I和131I显像。与诊断性131I扫描相比,124I PET/CT可检出更多病灶(120 vs 52);与治疗后131I扫描相比,124I PET检出病灶数略多(410 vs 390)。基于124I PET/CT,15-21%患者TNM分期被修正,5-29%患者疾病管理发生改变。
要点
- 与诊断性131I扫描相比,124I PET/CT可检出更多病灶(120 vs 52)。
- 在131I治疗初治、病理侵袭性较低或无弥漫性肺转移患者中,124I PET可能优于治疗后131I扫描。
- 基于124I PET/CT,15-21%患者TNM分期修正,5-29%管理改变。
核心结论
- 与诊断性131I扫描相比,124I PET/CT能识别更多病灶。
- 在131I治疗初治、病理侵袭性较低或无弥漫性肺转移患者中,124I PET可能比治疗后131I扫描检出更优。
- 124I PET额外检出的转移病灶可能对部分患者131I治疗前的管理有显著临床影响。
研究设计与样本
- 文献综述,检索MEDLINE、EMBASE、Northern Lights等数据库,覆盖1996年至2018年4月。
- 纳入4项回顾性和10项前瞻性研究,共495例分化型甲状腺癌患者接受124I和131I显像;无研究比较123I。
主要发现
- 比较124I PET/CT与诊断性131I扫描的研究中,72例患者124I检出120个病灶,诊断性131I仅检出52个。
- 比较124I与治疗后131I扫描的研究中,266例患者124I PET检出410个病灶,治疗后131I检出390个。
- 基于6项研究的124I PET/CT,15-21%患者TNM分期被修正,5-29%患者疾病管理发生改变。
临床怎么用
- 124I PET/CT可在131I治疗前提供更全面的病灶评估,可能影响部分患者的TNM分期和治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Studies report a wide spectrum of 124I positron emission tomography (PET)/computed tomography (CT) sensitivity and specificity in the detection of differentiated thyroid cancer (DTC) lesions. This study reviews the lesion detection rate of pretherapy 124I PET/CT in different patient populations and further analyzes the factors necessary for a better detection on 124I PET/CT. Methods: A literature search was performed using multiple different databases (MEDLINE, EMBASE, Northern Lights, and handsearching) covering 1996 to April 2018. Two reviewers reviewed and extracted study data for 124I, 123I, and 131I scans in DTC. Results: This review includes 4 retrospective and 10 prospective studies in which 495 DTC patients underwent 124I and 131I imaging; no studies made comparisons with 123I. In the reports that compared 124I PET/CT with diagnostic 131I scans, there were a total of 72 patients in whom 120 lesions were detected on 124I imaging, whereas only 52 were detected on diagnostic 131I scans. In publications that compared 124I with post-therapy 131I scans in 266 patients, 410 lesions were detected with 124I PET, whereas 390 were detected on post-therapy 131I scans. Based on 124I PET/CT in six studies, TNM staging was revised in 15-21% of patients, and disease management was altered in 5-29% of patients. Conclusions:124I PET/CT is able to identify a greater number of foci compared with diagnostic 131I scans. 124I PET may have better detection compared with post-therapy 131I scans in patients who are 131I therapy naive, have less aggressive pathology, or do not have disseminated lung metastases. Additional metastatic lesion detection by 124I PET may have a significant clinical impact in the management of patients before 131I therapy in some patients.
引用
- Wu D, Ylli D, Heimlich SL, et al. 124I Positron Emission Tomography/Computed Tomography Versus Conventional Radioiodine Imaging in Differentiated Thyroid Cancer: A Review. Thyroid. 2019. PMID: 31452449. doi:10.1089/thy.2018.0598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。